Ceftriaxone DALI Pharma 2 g Powder for Solution for Infusion

Country: Մալթա

language: անգլերեն

source: Medicines Authority

buyitnow

PIL PIL (PIL)
01-01-2022
SPC SPC (SPC)
01-01-2022

active_ingredient:

CEFTRIAXONE SODIUM

MAH:

DALI Pharma GmbH Brehmstrasse 56, 40239, Dusseldorf,, Germany

ATC_code:

J01DD04

INN:

CEFTRIAXONE SODIUM 2 g

pharmaceutical_form:

POWDER FOR SOLUTION FOR INFUSION

composition:

CEFTRIAXONE SODIUM 2 g

prescription_type:

POM

therapeutic_area:

ANTIBACTERIALS FOR SYSTEMIC USE

leaflet_short:

Licence number in the source country: NOT APPLICAPABLE

authorization_status:

Authorised

authorization_date:

2020-11-05

PIL

                                Page
1
of
10
PACKAGE LEAFLET: INFORMATION FOR THE USER
CEFTRIAXONE DALI PHARMA 2 G POWDER FOR SOLUTION FOR INFUSION
_Ceftriaxone _
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
−
Keep this leaflet. You may need to read it again.
−
If you have any further questions, ask your doctor, pharmacist or
nurse.
−
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
−
Ifyou get any side effects,talk to your doctor, pharmacist or
nurse.This includes any
possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ceftriaxone DALI Pharma is and what it is used for
2.
What you need to know before you are given Ceftriaxone DALI Pharma
3.
How Ceftriaxone DALI Pharma is given
4.
Possible side effects
5.
How to store Ceftriaxone DALI Pharma
6.
Contents of the pack and other information
1.
WHAT CEFTRIAXONE DALI PHARMA IS AND WHAT IT IS USED FOR
Ceftriaxone DALI Pharma contains the active substance ceftriaxone
whichis an antibiotic given
to adults and children (including newborn babies). It works by killing
bacteria that cause
infections. It belongs to a group of medicines called cephalosporins
_. _
Ceftriaxone DALI Pharma is used to treat infections of:
−
the brain (meningitis);
−
the lungs;
−
the abdomen and abdominal wall (peritonitis);
−
the urinary tract and kidneys;
−
bones and joints;
−
the skin or soft tissues;
−
the blood;
−
the heart.
Ceftriaxone DALI Pharma can be given:
−
to treat specific sexually transmitted infections (syphilis);
−
to treat patients with low white blood cell counts (neutropenia) who
have fever due to
bacterial infection;
−
to treat infections of the chest in adults with chronic bronchitis;
−
to treat Lyme disease (caused by tick bites) in adults and children
including newborn
babies from 15 days of age;
−
to prevent infections during surgery.
2.
WHAT YOU NEED TO
                                
                                read_full_document
                                
                            

SPC

                                Page
1
of
17
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Ceftriaxone DALI Pharma 2 g Powder for Solution for Infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 2 g of ceftriaxone (as ceftriaxone sodium).
Excipient with known effect:
This medicinal product contains approximately 166 mg (7.2 mmol) of
sodium per 2 grams of
ceftriaxone.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for infusion.
An almost white or yellowish crystalline powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ceftriaxone DALI Pharma is indicated for the treatment of the
following infections in adults
and children including term neonates (from birth):
−
bacterial meningitis;
−
community acquired pneumonia;
−
hospital acquired pneumonia;
−
intra-abdominal infections;
−
complicated urinary tract infections (including pyelonephritis);
−
infections of bones and joints;
−
complicated skin and soft tissue infections;
−
syphilis;
−
bacterial endocarditis.
Ceftriaxone DALI Pharma may be used:
−
for treatment of acute exacerbations of chronic obstructive pulmonary
disease in adults;
−
for treatment of disseminated Lyme borreliosis (early (stage II) and
late (stage III)) in
adults and children including neonates from 15 days of age;
−
for pre-operative prophylaxis of surgical site infections;
−
in the management of neutropenic patients with fever that is suspected
to be due to a
bacterial infection;
−
in the treatment of patients with bacteraemia that occurs in
association with, or is
suspected to be associated with, any of the infections listed above.
Ceftriaxone DALI Pharma should be co-administered with other
antibacterial agents whenever
the possible range of causative bacteria would not fall within its
spectrum (see section 4.4).
Page
2
of
17
Consideration should be given to official guidelines on the
appropriate use of antibacterial
agents.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The dose depends on the seve
                                
                                read_full_document